DOCSLIB.ORG

WHO Drug Information Vol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WHO Drug Information Vol WHO Drug Information Vol. 28 No. 1, 2014 WHO Drug Information Contents Regulatory harmonization Strontium ranelate: further restrictions The International Generic Drug due to cardiovascular risks 25 Regulators Pilot 3 Methysergide-containing medicines: new WHO support for medicines regulatory restrictions 25 harmonization in Africa: focus on East African Community 11 Regulatory action and news Regulatory options in the fight against Technologies, standards and norms antimicrobial resistance 26 Standards for biological products 16 EMA and FDA collaborate on bioequivalence inspections 26 Safety and efficacy issues Tafenoquine receives FDA Breakthrough Combined hormonal contraceptives and Therapy designation 27 venous thromboembolism 21 Regulatory action against Ranbaxy’s Clobazam: serious skin reactions 21 Toansa facility 27 Amiodarone: pulmonary toxicity 21 WHO response to FDA findings at Methylphenidate: rare risk of long-lasting Ranbaxy’s Toansa site 27 erections in males 22 New partnership to strengthen regulatory Glibenclamide: risk of hypoglycaemia in systems 27 elderly and renal-impaired patients 22 Canada-US Common Electronic Subcutaneous epoetin alfa: Submissions Gateway 28 contraindicated in Singapore in chronic Updated guidance for annual strain kidney disease patients 22 change of seasonal influenza vaccines 28 Acipimox: only to be used as additional or EMA and FDA strengthen collaboration on alternative treatment 22 pharmacovigilance 28 Estradiol-containing creams: new European Medicines Agency publishes restrictions 23 first summary of a risk-management Clopidogrel: rare reports of acquired plan for a medicine 29 haemophilia 23 EMA and FDA extend parallel assessment Sodium phosphate products in high pilot 29 doses: severe dehydration 23 Australia and New Zealand harmonization Emergency contraceptives – high activities 29 bodyweight may reduce effectiveness 24 ► Approvals Testosterone: possible risk of stroke and First adjuvanted vaccine for H5N1 avian heart attack 24 influenza approved 29 Lithium: hypercalcaemia and Umeclidinium and vilanterol approved for hyperparathyroidism 24 chronic obstructive pulmonary disease 30 Saxagliptin: possible risk of heart failure 25 Dapaglifozin approved for type 2 diabetes 30 Continued 1 WHO Drug Information Vol. 28 No. 1, 2014 Continued Trametinib and dabrafenib approved in Atazanavir capsules 38 combination for advanced melanoma 30 Implementation of the revised general Droxidopa approved for neurogenic monograph on parenteral preparations orthostatic hypotension 31 in The International Pharmacopoeia: Bedaquiline recommended for approval to Limits for the test for bacterial treat multidrug-resistant tuberculosis 31 endotoxins (3.4) 41 Metreleptin approved to treat rare Revision of general monograph: metabolic disease 31 Suppositories 45 Revision of method of analysis: Recent publications, information 5.3 Disintegration test for tablets and and events capsules 50 World malaria report: financing needed to Revision of method of analysis: sustain major progress 32 5.4 Disintegration test for suppositories WHO Prequalification: A quiet revolution and rectal capsules 54 in global public health 32 RADIOPHARMACEUTICALS: 56 AIDS drugs for all: how global advocacy Sodium iodide (131I) solution 56 transformed pharmaceutical markets 33 Technetium (99mTc) exametazime complex Who are the originators of innovative injection 59 medicines in the EU? 33 Thallous (201Tl) chloride injection 63 Medicines Patent Pool and Bristol-Myers Squibb sign agreement 33 ATC/DDD Classification Report calls for cooperation to strengthen ATC/DDD Classification (Temporary) 66 post-market surveillance systems 34 ATC/DDD Classification (Final) 69 ► Events Annual ATC/DDD Methodology course 34 International Nonproprietary Names Recommended List No. 71 71 Consultation documents ► The International Pharmacopoeia Atazanavir sulfate 35 WHO Drug Information is available electronically at http://www.who.int/medicines/publications/druginformation/en/ International Conference of Drug Regulatory Authorities (ICDRA) The 16th ICDRA will be hosted by the Brazilian National Health surveillance Agency (ANVISA) Rio de Janeiro, Brazil 24 - 29 August 2014 http://www.icdra.com.br/ 2 WHO Drug Information Vol. 28 No. 1, 2014 Regulatory harmonization The International Generic Drug Regulators Pilot The pre-market review of generic medicines puts mounting pressures on health regulatory authorities around the world due to increasing workloads and risks associated with complex global supply chains. This has led a group of regulators to launch the International Generic Drug Regulators Pilot (IGDRP), aimed at regulatory convergence and cooperation. The three-year pilot entails a series of concrete measures to facilitate the timely authorization and availability of safe, effective and quality generic medicines. Results of the pilot will inform decisions on establishing a more permanent information and work-sharing arrangement as part of broader international efforts related to regulation of medicines. The success of the initiative will require the support of industry as well as other stakeholders interested in promoting access to affordable, quality generic medicines. Introduction regions become aligned over time as the The availability of quality generic drugs, same harmonized technical guidance also known as multi-source medicines or documents, standards and scientific pharmaceuticals, plays an increasingly principles are adopted and similar important role in helping to address rising regulatory practices and procedures are health care costs and in promoting access introduced. Regulatory convergence in turn to essential medicines worldwide. This, makes possible additional, enhanced forms however, has led to significant pressures of cooperation and collaboration between on medicines regulatory authorities (RAs) regulatory authorities. charged with the review and approval of these products. In addition to an increased Exploratory meeting workload associated with the growing In an effort to address the challenges number of generic drug applications, associated with the increasingly RAs must now also contend with more demanding review of generic drug sophisticated generic drug products and applications, regulatory authorities from complex global production and distribution Australia, Brazil, Canada, the European chains. Union, the Republic of Korea, Singapore, Given these challenges, the need for Switzerland and the United States as well regulatory cooperation and convergence as the World Health Organization (WHO) has long been recognized. “Regulatory met in Ottawa in October 2011 to explore convergence” represents a process opportunities for collaboration. A number whereby the regulatory requirements of positive developments and precedents and approaches across countries and were identified that favour a collaborative drug review model, including: Article by Mike Ward, Manager, International • a common set of quality requirements Programs, Therapeutic Products Directorate, and application format provided by ICH Health Products and Food Branch, Health Canada. 3 Regulatory harmonization WHO Drug Information Vol. 28 No. 1, 2014 Quality guidelines (1) and the Common Findings from the surveys and views Technical Document (CTD); expressed in the exploratory meeting • the increasing number of multi-national confirmed strong support in principle for generic companies, including the regulatory collaboration in the pre-market generic arm of innovator companies, review of generic drugs, although the with a potential for common products, degree of support was conditional for some ingredients and manufacturing sites RAs on the scope and form of collaborative across markets; model chosen. In general, there was • the success of existing collaborative also agreement on the main advantages, models, including the WHO’s challenges and enablers to international Prequalification Programme as well as collaboration (Table 1). Although important the EU’s Centralised and Decentralised challenges were identified, they were not Procedures (and the EU’s Mutual felt to be insurmountable. Recognition Procedure, wherein a marketing authorization has already The path forward been granted by an EU Member State); Recommendations from the exploratory and meeting helped to shape the path • the restricted set of scientific disciplines forward. Key among these was the need involved in generic drug reviews, to be pragmatic and to adopt a step-wise compared with reviews of first market approach, starting with selected areas entry drugs (“new drugs”). of collaboration, a mapping of regulatory programmes and information-sharing Preliminary surveys between authorities. The meeting in Ottawa was preceded It was also recognized that many of the by surveys, commissioned by Health prerequisites for collaborative generic Canada, with a number of multi-national drug review – such as secure electronic generic drug manufacturers and with the platforms for sharing of documents, participating RAs. Regulatory frameworks, and mechanisms to treat and exchange data exclusivity, patent rules, submission confidential business information – management and other pertinent issues also apply to other areas of potential were also compared to help inform cooperation. Finding solutions to these discussions. issues, together with the building of greater RAs were asked about the potential knowledge and trust between regulatory advantages and disadvantages of a authorities, will facilitate additional areas of
Load more

Recommended publications
  • Chapter 7: Monogenic Forms of Diabetes
    CHAPTER 7 MONOGENIC FORMS OF DIABETES Mark A. Sperling, MD, and Abhimanyu Garg, MD Dr. Mark A. Sperling is Emeritus Professor and Chair, University of Pittsburgh, Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA. Dr. Abhimanyu Garg is Professor of Internal Medicine and Chief of the Division of Nutrition and Metabolic Diseases at University of Texas Southwestern Medical Center, Dallas, TX. SUMMARY Types 1 and 2 diabetes have multiple and complex genetic influences that interact with environmental triggers, such as viral infections or nutritional excesses, to result in their respective phenotypes: young, lean, and insulin-dependence for type 1 diabetes patients or older, overweight, and often manageable by lifestyle interventions and oral medications for type 2 diabetes patients. A small subset of patients, comprising ~2%–3% of all those diagnosed with diabetes, may have characteristics of either type 1 or type 2 diabetes but have single gene defects that interfere with insulin production, secretion, or action, resulting in clinical diabetes. These types of diabetes are known as MODY, originally defined as maturity-onset diabetes of youth, and severe early-onset forms, such as neonatal diabetes mellitus (NDM). Defects in genes involved in adipocyte development, differentiation, and death pathways cause lipodystrophy syndromes, which are also associated with insulin resistance and diabetes. Although these syndromes are considered rare, more awareness of these disorders and increased availability of genetic testing in clinical and research laboratories, as well as growing use of next generation, whole genome, or exome sequencing for clinically challenging phenotypes, are resulting in increased recognition. A correct diagnosis of MODY, NDM, or lipodystrophy syndromes has profound implications for treatment, genetic counseling, and prognosis.
    [Show full text]
  • Myalept® (Metreleptin)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 2032-11 Program Prior Authorization/Medical Necessity Medication Myalept® (metreleptin) P&T Approval Date 5/2014, 7/2014, 8/2014, 7/2015, 6/2016, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021 Effective Date 8/1/2021; Oxford only: 8/1/2021 1. Background: Myalept (metreleptin) is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.1 Myalept is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS), called the Myalept REMS program, because of the risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and the risk of lymphoma. 2. Coverage Criteria: A. Initial Authorization 1. Myalept will be approved based on all of the following criteria: a. Diagnosis of congenital or acquired generalized lipodystrophy associated with leptin deficiency -AND- b. Myalept is being used as an adjunct to diet modification -AND- c. Prescribed by an endocrinologist -AND- d. Documentation demonstrates that patient has at least one of the following: (1) Diabetes mellitus or insulin resistance with persistent hyperglycemia (HgbA1C > 7.0) despite both of the following: (a) Dietary intervention (b) Optimized insulin therapy at maximum tolerated doses © 2021 UnitedHealthcare Services, Inc. 1 -OR- (2) Persistent hypertriglyceridemia (TG > 250) despite both of the following: (a) Dietary intervention (b) Optimized therapy with at least two triglyceride-lowering agents from different classes (e.g., fibrates, statins) at maximum tolerated doses Authorization will be issued for 12 months B.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Comparison of Efficacy of Combination of 2% Ketoconazole
    Open Access Original Article Comparison of Topical Treatments in Pityriasis Versicolor Pak Armed Forces Med J 2018; 68 (6): 1725-30 COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR Ayesha Anwar, Naeem Raza, Najia Ahmed, Hyder Ali Awan* Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *King Abdul Aziz Naval Base, Jubail, Saudia Arabia ABSTRACT Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor. Study Design: Randomized controlled trial. Place and Duration of Study: Dermatology department, Pak Emirates Military Hospital Rawalpindi, from Oct 2016 to Apr 2017. Material and Methods: Sixty patients of Pityriasis versicolor, both male and female were included in study. Diagnosis of Pityriasis versicolor was made clinically and confirmed microscopically by examining skin scrapings for fungal hyphae. Patients with concomitant systemic illnesses or those who had received anti-fungal in last three months were excluded from study. Random number tables were used to allocate patients to the two treatment groups. Group A received 2% ketoconazole shampoo twice per week for four weeks plus topical 1% clotrimazole twice daily application for 2 weeks. Group B received only topical therapy with 1% clotrimazole cream applied twice daily for 2 weeks. Assessment of treatment efficacy was done by clinical examination of patient and microscopy of skin scrapping for fungal hyphaedone at baseline and at end of study (4 weeks of treatment). A negative clinical examination and negative skin scrapping for fungal hyphae was considered effective therapeutic response.
    [Show full text]
  • Putting Medications in Perspective for Chronic Weight Management
    05/06/2019 1 Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Baton Rouge, LA, USA The Role of Pharmacology in Weight Management: Putting Medications in Perspective for Chronic Weight Management 1 Disclosures • Consulting fee: Amgen, Gila Therapeutics, IFA Celtic, Novo Nordisk, Bausch Health, Real Appeal, Sanofi, Quintiles Novella, Paul Hastings, Simmons and Simmons, ReDesign Health, KVK Tech • Speakers bureau: Novo Nordisk, Bausch Health • Equity: Gila Therapeutics, Scientific Intake, Epitomee, ReDesign Health 2 05/06/2019 2 Objectives At the end of the session, attendees will be able to • identify when to start a weight loss medication, • identify how to choose the right one for the right patient, • identify when to combine approaches for better results and • discuss future prospects in obesity pharmacotherapy. • 3 Should we treat obesity with drugs? 4 05/06/2019 3 Should we treat obesity with drugs? No! not by themselves Yes! when patients need help • Drugs don’t work on their own. • For patients who struggle to lose They work through biology to enough weight to get health reinforce the patient’s intention to benefits, drugs can help them adhere to a dietary plan. Better better adhere to the dietary plan adherence = more weight loss. to lose more weight. Drugs also Drugs also sustain lost weight as sustain weight loss as long as they long as they are taken. are taken. 5 Rationale for Medications in Obesity Management • Food intake is biologically determined. • Weight loss is opposed and regain promoted by physiology of reduced obese state. • Medications work through biology of appetite regulation to help patients adhere to diet plans.
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Comparison of Topical Anti- Fungal Agents Sertaconazole And
    DOI: 10.7860/JCDR/2014/10210.4866 Original Article Comparison of Topical Anti- Fungal Agents Sertaconazole and Pharmacology Section Clotrimazole in the Treatment of Tinea Corporis-An Observational Study RAGHU PRASADA MALLADAR SHIVAMURTHY1, SHASHIKALA GOWDARA HANUMANTAPPA REDDY2, RAVINDRA KALLAPPA3, SHANKAR ACHAR SOMASHEKAR4, DEEPA PATIL5, UMAKANT N PATIL6 ABSTRACT Results: The total score included all grades in erythema, Objectives: To compare the efficacy of topical antifungal agents, itching, scaling, margins and size of lesion and KOH mount. Sertaconazole and Clotrimazole in Tinea corporis patients. There was significant reduction in erythema (p<0.02) and highly significant reduction in scaling (p<0.001), itching (p<0.001) and Materials and Methods: A total of 60(n=60) patients were margins of lesion (p<0.001) among Sertaconazole group. The included in the study. They were divided into two groups of mean difference and the standard deviation of total scores for 30 patients each. First group included patients treated with Clotrimazole were 7.20 and 1.69 and for Sertaconazole group topical Sertaconazole as test drug whereas the second group 8.80 and 1.52 respectively. The p-value on application of constituted patients treated with topical Clotrimazole as students unpaired t- test was p<0.001 (Highly significant). standard drug. The patients were advised to apply the drug on affected area twice daily for three weeks. The parameters like Conclusion: From the present study, it can be concluded that erythema, scaling, itching, margins and size of the lesion and topical Sertaconazole shows better improvement in the clinical KOH mount were taken for the assessment of efficacy.
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]